Maurice Zauderer - 06 Dec 2022 Form 4 Insider Report for VACCINEX, INC. (VCNX)

Role
President and CEO, Director, 10%+ Owner
Signature
/s/ Scott E. Royer, Attorney-in-Fact for Maurice Zauderer
Issuer symbol
VCNX
Transactions as of
06 Dec 2022
Transactions value $
$0
Form type
4
Date filed
07 Dec 2022, 15:30
Previous filing
28 Nov 2022
Next filing
03 Apr 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VCNX Common Stock Will/Inheritance $0 +3.99K +2.24% $0.00 182K 06 Dec 2022 Direct
holding VCNX Common Stock 213K 06 Dec 2022 By Jeremy C. Zauderer Trust F1
holding VCNX Common Stock 212K 06 Dec 2022 By Jordan M. Zauderer Trust F1
holding VCNX Common Stock 4.41M 06 Dec 2022 By Vaccinex (Rochester), L.L.C. F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding VCNX Stock Option (Right to Buy) 2.59K 06 Dec 2022 Common Stock 2.59K $14.90 Direct F3
holding VCNX Stock Option (Right to Buy) 2.59K 06 Dec 2022 Common Stock 2.59K $14.90 Direct F3
holding VCNX Stock Option (Right to Buy) 3.33K 06 Dec 2022 Common Stock 3.33K $7.10 Direct F3
holding VCNX Stock Option (Right to Buy) 20K 06 Dec 2022 Common Stock 20K $4.29 Direct F4
holding VCNX Stock Option (Right to Buy) 28.4K 06 Dec 2022 Common Stock 28.4K $6.68 Direct F5
holding VCNX Stock Option (Right to Buy) 14K 06 Dec 2022 Common Stock 14K $2.93 Direct F6
holding VCNX Stock Option (Right to Buy) 28K 06 Dec 2022 Common Stock 28K $1.29 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Dr. Zauderer exercises voting control over shares held by this trust and disclaims beneficial ownership over these shares except to the extent of his pecuniary interest therein.
F2 Dr. Zauderer is the president and a majority owner of Vaccinex (Rochester), L.L.C. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
F3 Exercisable in full as of the date of this report.
F4 This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the March 15, 2019 grant date.
F5 This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the February 25, 2020 grant date.
F6 This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the April 2, 2021 grant date.
F7 This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the April 1, 2022 grant date.